Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy

Shingo Yokoyama, Kota Kakeshita, Teruhiko Imamura*, Tomoko Shima, Hayato Fujioka, Hidenori Yamazaki, Tsutomu Koike, Koichiro Kinugawa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Pegylated liposomal doxorubicin (PLD) has emerged as a recent innovation within the realm of antineoplastic agents, distinguished by its incorporation of doxorubicin within the liposomal bilayer. Given the low risk of cardiotoxicity, the clinical use of PLD has been expanding. We encountered a patient who underwent extended PLD therapy for recurrent malignancy and subsequently developed PLD-associated thrombotic microangiopathy, which was diagnosed by a detailed pathophysiological assessment. This case underscores the importance of considering thrombotic microangiopathy as a potential differential diagnosis in patients presenting with unexplained hypertension and renal impairment during prolonged PLD monotherapy.

Original languageEnglish
Pages (from-to)2839-2845
Number of pages7
JournalInternal Medicine
Volume63
Issue number20
DOIs
StatePublished - 2024

Keywords

  • drug induced kidney injury
  • liposome
  • ovarian cancer
  • polyethylene glycol (PEG)
  • proteinuria

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy'. Together they form a unique fingerprint.

Cite this